|
|
| | (1R,2S,3S)-Aprepitant Basic information |
| Product Name: | (1R,2S,3S)-Aprepitant | | Synonyms: | Aretetan Impurity-(RSS);5-([(2S,3S)-2-((R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluoro phenyl)morpholino]methyl)-1H-1,2,4-triazol-3(2H)-one;3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2S-[2α(S*),3β]]- (9CI);SM001F;(2S,3S,1’R)-Aprepitant;Aprepitant Impurity - (RSS);Aprepitant Intermediate Impurity -(RSS);Aprepitant impurity 7/(1R,2S,3S)-Aprepitant | | CAS: | 172822-28-5 | | MF: | C23H21F7N4O3 | | MW: | 534.43 | | EINECS: | | | Product Categories: | | | Mol File: | 172822-28-5.mol |  |
| | (1R,2S,3S)-Aprepitant Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | pka | 8.06±0.20(Predicted) |
| | (1R,2S,3S)-Aprepitant Usage And Synthesis |
| Uses | (2S,3S,1’R)-Aprepitant is an impurity of Aprepitant (A729800); a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic. (2S,3S,1’R)-Aprepitant is also a useful synthetic intermediate in the synthesis of morpholine tachykinin receptor antagonist prodrugs. |
| | (1R,2S,3S)-Aprepitant Preparation Products And Raw materials |
|